Tesamorelin Reduces Hepatic Steatosis in HIV-Associated Non-Alcoholic Fatty Liver Disease | RemedyX Labs Research Library

A research summary of Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial, examining tesamorelin reduces hepatic steatosis in hiv-associated non-alcoholic fatty liver disease. Cited source and RUO context from RemedyX Labs.